临床试验/NCT06823050

NCT06823050尚未招募不适用

A Prospective, Multicenter, Phase II Clinical Study on the Treatment of Unresectable Advanced Hepatocellular Carcinoma with the DEB-TACE (drug-loaded Microsphere Transcatheter Arterial Chemoembolization) Combined with Hepatic Artery Perfusion of Raltitrexed and Oxaliplatin (SALOX-HAIC) Regimen

Xuhua Duan7 个研究点分布在 1 个国家目标入组 59 人开始时间: 2025年3月1日最近更新: 2025年2月12日

适应症

试验速览

阶段: 不适用
状态: 尚未招募
发起方
入组人数: 59
试验地点: 7
主要终点: Progression-free survival (PFS)

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The aim of this study is to clarify the safety and efficacy of DEB-TACE combined with SALOX-HAIC in the treatment of unresectable advanced primary liver cancer. To determine whether this therapy can prolong the indicators such as PFS, TTP, OS, ORR, and DOR.

研究设计

研究类型: Observational
观察模型: Other
时间视角: Prospective

入排标准

年龄范围: 18 Years 至 80 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Patient with unresectable HCC who strictly meet the clinical diagnostic criteria of the Guidelines for Diagnosis and Treatment of Primary Liver Cancer (2024 Edition) or who have been confirmed by histopathology or cytology, There was at least one measurable lesion (according to the requirements of mRECIST 1.1, the spiral CT scan diameter of the measurable lesion was ≥10mm or the short diameter of enlarged lymph node was ≥15mm).
•CNLC Ib-IIIa；BCLC：A-C
•Patient age between 18 and 80，male or female.
•5.Expected life span ≥ 3 months.
•No history of severe comorbidities, such as hypertension, coronary heart disease, and mental illness, and no history of severe allergies.
•Child-Pugh A-B. 8.The laboratory tests meet the following requirements: platelets ≥ 50×109/L; hemoglobin ≥ 9g/dL; white blood cells ≥ 4×109/L; neutrophils ≥ 1.5×109/L; serum total bilirubin ≤ 1.5 times the upper limit of normal value (ULN), transaminases (ALT, AST) ≤ 5 times ULN; creatinine ≤ 1.5 times ULN; urine routine test shows that urine protein < 2+; for patients whose urine routine test at baseline showed urine protein ≥ 2+, 24-hour urine collection should be conducted and the 24-hour urine protein quantification should be < 1g; international normalized ratio (INR) or activated partial thromboplastin time (APTT) ≤ 1.5 times ULN.
•HBV DNA<2000 IU/ml.
•Women of childbearing age must undergo a pregnancy test within 7 days prior to enrollment.
•Patients sign informed consent, good compliance, cooperate with treatment.

排除标准

•Imaging examinations were conducted for HCC patients with large liver tumors (≥60% of liver volume), or carcinoma thrombus in main portal vein (occupying ≥50% of vascular diameter), or carcinoma thrombus invading mesenteric vein or inferior vena cava, or significant arteriovenous/venous fistula.
•Before participating in this study, she had received local treatment such as TACE, external radiotherapy and radioactive particle implantation, and had undergone systemic chemotherapy, oral liver cancer targeting drugs (Sorafenib, Lenfacitinib, Apatinib) and immunotherapy such as PD-1/PD-L1/CDLA-
•Diffuse liver cancer patients.
•Patients with grade Ⅱ or above myocardial ischemia or myocardial infarction, poorly controlled arrhythmias (including QTc interval ≥450ms for men and 470ms for women.
•A history of gastrointestinal bleeding within the past 6 months or a definite tendency to gastrointestinal bleeding.
•Abnormal clotting function, bleeding tendency or receiving thrombolytic or anticoagulant therapy.
•Patients with central nervous system metastases or known brain metastases. Co-infected patients with HIV; Pregnant or lactating patients. Patients preparing for liver transplantation (other than those with previous liver transplantation.
•Systemic failure, estimated survival time <3 months.
•Severe renal dysfunction.
•The patients could not complete the treatment plan due to various reasons, and lost control within three months after enrollment.

结局指标

主要结局

Progression-free survival (PFS)

时间窗: Time from the first DEB-TACE treatment to either radiological progression or death or up to 24 months

次要结局

Overall survival (OS)(Time Frame: Time from the first DEB-TACE treatment to death or up to 24 months)
Objective response rate (ORR)(1, 3, 6,12,18,24 months after the first DEB-TACE treatment, up to death or 24 months, whichever came first.)
Disease control rate (DCR)(1, 3, 6,12,18,24 months after the first DEB-TACE treatment, up to death or 24 months, whichever came first)
Time to Progression (TTP)(Time from the first DEB-BACE treatment to either radiological progression up to 24 months)

研究者

发起方

Xuhua Duan

申办方类型

Other

责任方

Sponsor Investigator

主要研究者

Xuhua Duan

Associate Professor

The First Affiliated Hospital of Zhengzhou University

研究点 (7)

Loading locations...

相似试验

进行中（未招募）

1 期

A prospective, multi-center, Phase 1b/2a study to assess the safety and tolerability of different doses of AG019 administered alone or in association with teplizumab in patients with clinical recent-onset Type 1 Diabetes Mellitus (T1D)Recent-onset Type 1 Diabetes mellitus (T1D)MedDRA version: 21.1Level: PTClassification code 10067584Term: Type 1 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disorders

EUCTR2017-002871-24-BEIntrexon T1D Partners, LLC (IT1D)48

进行中（未招募）

1 期

Study of HM15912 in subjects with Short Bowel Syndrome-associated Intestinal FailureShort Bowel Syndrome-associated Intestinal Failure (SBS-IF)MedDRA version: 20.1Level: PTClassification code 10049416Term: Short-bowel syndromeSystem Organ Class: 10017947 - Gastrointestinal disorders

EUCTR2021-000176-11-DEHanmi Pharmaceutical Co., Ltd.18

进行中（未招募）

1 期

Study of HM15912 in subjects with Short Bowel Syndrome-associated Intestinal FailureShort Bowel Syndrome-associated Intestinal Failure (SBS-IF)MedDRA version: 20.1Level: PTClassification code: 10049416Term: Short-bowel syndrome Class: 100000004856

CTIS2024-515160-32-00Hanmi Pharm. Co. Ltd.16

进行中（未招募）

1 期

Study of HM15912 in subjects with Short Bowel Syndrome-associated Intestinal Failure

EUCTR2021-000176-11-DKHanmi Pharmaceutical Co., Ltd.18

进行中（未招募）

1 期

EUCTR2021-000176-11-BEHanmi Pharmaceutical Co., Ltd.18